Salt, Sodium & Potassium and Blood Pressure: Independent Evidence
Less salt lowers blood pressure; potassium salt cut strokes in one large trial but carries a kidney risk. Who funds the evidence, and where Graudal and He differ.
Evidence-graded research on blood pressure and hypertension — which lifestyle steps and supplements are backed by primary human trials, conflicts disclosed.
Less salt lowers blood pressure; potassium salt cut strokes in one large trial but carries a kidney risk. Who funds the evidence, and where Graudal and He differ.
Indapamide, chlortalidone, bendroflumethiazide and hydrochlorothiazide compared: stroke and heart evidence, sodium, gout, skin-cancer warnings and who funded the trials.
Renal denervation lowers blood pressure modestly versus sham, after a first major trial was negative. Who funded the evidence, safety and approval status.
Hibiscus tea and beetroot juice may lower systolic blood pressure by a few points, but trials are small, products vary and some juice trials had supplier ties.
How ABPM and home monitoring find white-coat and masked hypertension, what the risk data show, the retracted 2018 study, treatment gaps and who funds the monitors.
What the 2025 Endocrine Society guideline, PATHWAY-2 and SPARTACUS show on primary aldosteronism screening, adrenal vein sampling and treatment, and who funded the evidence.
Aspirin, blood pressure medicines, magnesium sulphate, calcium and PlGF tests for pregnancy hypertension, with the trials’ funders and later heart risk.
Doxazosin relieves prostate symptoms but failed as a first-line blood pressure drug in ALLHAT. We trace the trials, the Pfizer funding and the safety risks.
Independent review of atenolol and older beta-blockers for hypertension: LIFE, ASCOT, Cochrane, NICE, side effects, diabetes, withdrawal, pregnancy and funding.
Diltiazem and verapamil: what independent trials show for blood pressure, AF rate control and cluster headache, plus heart failure, beta-blocker and simvastatin risks.
Get the topics, key findings and links from our new articles in one email. At most one digest a day, only when there is something new.